Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 7/20 | 0.38 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744834 | 0.86 | PSMB5 (0.40) | PSMB5PSMB1PTGS2KDRCCNE1 | |
| SCHEMBL2744786 | 0.79 | PSMB5 (0.34) | PSMB5PSMB1PTGS2KDRCCNE1 | |
| SCHEMBL27173426 | 0.77 | PSMB5 (0.45) | PSMB5PSMB1PTGS2KDRCCNE1 | |
| SCHEMBL4425866 | 0.71 | PTGS2 (0.47) | PSMB5PSMB1PTGS2TDP1 | |
| SCHEMBL7203713 | 0.70 | ACMSD (0.37) | PSMB5PSMB1PTGS2CCNE1CDK2 | |
| Hydrochloric Acid SCHEMBL29019116 | 0.69 | TYMP (0.39) | PSMB5PSMB1PTGS2CCNE1CDK2 | |
| SCHEMBL296554 | 0.68 | TYMP (0.42) | PSMB5PSMB1PTGS2CCNE1CDK2 | |
| SCHEMBL7253177 | 0.68 | ESR1 (0.33) | — | |
| SCHEMBL9672196 | 0.68 | NR1I2 (0.31) | — | |
| SCHEMBL8219666 | 0.67 | PSMB5 (0.39) | PSMB5PSMB1PTGS2KDRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274706-A1 | PYRAZOLES FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2003-01-15 | — | — | EP | disclosed |
| US-6462069-B2 | KINASE INHIBITORS; ANTICANCER AGENTS | AGOURON PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020006952-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases | LIGHPOINTE COMMUNICATION, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001079198-A1 | PYRAZOLES FOR INHIBITING PROTEIN KINASE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006952-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases | CDK3, CCNK, CDK1 | PSMB5 1423/4885PSMB1 1582/4885PTGS2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.